KR890002141A - 무정형 아즈트레오남 - Google Patents

무정형 아즈트레오남 Download PDF

Info

Publication number
KR890002141A
KR890002141A KR1019880007972A KR880007972A KR890002141A KR 890002141 A KR890002141 A KR 890002141A KR 1019880007972 A KR1019880007972 A KR 1019880007972A KR 880007972 A KR880007972 A KR 880007972A KR 890002141 A KR890002141 A KR 890002141A
Authority
KR
South Korea
Prior art keywords
amorphous
amino
aztreonam
arginine
compound
Prior art date
Application number
KR1019880007972A
Other languages
English (en)
Korean (ko)
Inventor
아밀랄 배리아 세일리쉬
유진 레이어 조오지
더글라스 핍킨 제임스
Original Assignee
니콜라스 피,말라에스티
이이.아트.스퀴부 앤드 산즈, 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니콜라스 피,말라에스티, 이이.아트.스퀴부 앤드 산즈, 인코오포레이티드 filed Critical 니콜라스 피,말라에스티
Publication of KR890002141A publication Critical patent/KR890002141A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019880007972A 1987-07-01 1988-06-30 무정형 아즈트레오남 KR890002141A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6839287A 1987-07-01 1987-07-01
US068,392 1987-07-01

Publications (1)

Publication Number Publication Date
KR890002141A true KR890002141A (ko) 1989-04-08

Family

ID=22082279

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880007972A KR890002141A (ko) 1987-07-01 1988-06-30 무정형 아즈트레오남

Country Status (9)

Country Link
EP (1) EP0297580B1 (fr)
JP (1) JP2701869B2 (fr)
KR (1) KR890002141A (fr)
CN (1) CN1028234C (fr)
AT (1) ATE175965T1 (fr)
CA (1) CA1339136C (fr)
DE (1) DE3856297T2 (fr)
ES (1) ES2127178T3 (fr)
GR (1) GR3029873T3 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191492B (fr) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
ATE399766T1 (de) 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
IL156596A0 (en) 2000-12-27 2004-01-04 Salus Pharma Inc Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
WO2004013133A1 (fr) 2002-08-05 2004-02-12 TEVA Gyógyszergyár Részvénytársaság Preparation d'aztreonam
WO2004052333A1 (fr) * 2002-12-11 2004-06-24 Pari Gmbh Compositions pharmaceutiques pour l'administration pulmonaire d'aztreonam
EP1604665B1 (fr) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. Inhibiteur de kinase c-kit
CN1802371A (zh) 2003-05-15 2006-07-12 特瓦药厂有限公司 残余溶剂含量极低的阿兹托南β多晶型
AU2004256124B2 (en) * 2003-07-02 2011-04-28 Corus Pharma, Inc. Aztreonam L-lysine and methods for the preparation thereof
WO2005063713A1 (fr) 2003-12-25 2005-07-14 Eisai Co., Ltd. Cristaux de sel de 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide ou de ses solvate, et leur procede de production
KR20070053205A (ko) 2004-09-17 2007-05-23 에자이 알앤드디 매니지먼트 가부시키가이샤 의약 조성물
JP2008505189A (ja) 2005-05-09 2008-02-21 シコール インコーポレイティド アズトレオナムの製造方法
AU2006260148B9 (en) * 2005-06-23 2009-09-17 Eisai R&D Managment Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)- 7-methoxy-6-quinolinecarboxamide and process for producing the same
US7550483B2 (en) 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
EP1925676A4 (fr) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Procédé d'analyse de l' effet d 'un inhibiteur de vascularisation
EP2036557B1 (fr) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Agent antitumoral destiné au cancer de la thyroïde
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101579336B (zh) * 2009-07-07 2010-06-23 重庆市庆余堂制药有限公司 一种注射用氨曲南及其生产方法
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
CN101912356B (zh) * 2010-08-02 2012-01-11 王明 一种氨曲南/精氨酸药物组合物脂微球注射剂
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
EP2937337A4 (fr) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd Forme amorphe de dérivé de quinoline et son procédé de production
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
TWI721954B (zh) 2014-08-28 2021-03-21 日商衛材R&D企管股份有限公司 高純度喹啉衍生物及其生產方法
RU2017128583A (ru) 2015-02-25 2019-03-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ ослабления горечи хинолинового производного
CA2978226A1 (fr) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1181075A (fr) * 1981-07-13 1985-01-15 David M. Floyd FORME CRISTALLISEE ANHYDRE DE L'ACIDE[3-S-[.alpha. (Z),4.beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL]AMINO ]-4-METHYL-2-OXO-1-AZETIDINESULFONIQUE
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile

Also Published As

Publication number Publication date
CA1339136C (fr) 1997-07-29
EP0297580B1 (fr) 1999-01-20
ATE175965T1 (de) 1999-02-15
ES2127178T3 (es) 1999-04-16
JPS6422874A (en) 1989-01-25
GR3029873T3 (en) 1999-07-30
JP2701869B2 (ja) 1998-01-21
EP0297580A1 (fr) 1989-01-04
CN1028234C (zh) 1995-04-19
DE3856297T2 (de) 1999-06-02
DE3856297D1 (de) 1999-03-04
CN1030238A (zh) 1989-01-11

Similar Documents

Publication Publication Date Title
KR890002141A (ko) 무정형 아즈트레오남
DE3769676D1 (de) Prodrugverbindungen, verfahren zu deren herstellung und diese enthaltende zubereitungen mit verzoegerter freisetzung.
BR9910928A (pt) Composto, processo para a prepará-lo, uso do mesmo, formulação, e, processo para a profilaxia e/ou tratamento de condições clinicas associadas com resistência a insulina
SE8304045D0 (sv) Derivat av morfolinyl-daunorubicin och morfolinyl-doxorubicin, och analoger derav samt forfarande for framstellning derav
ES514267A0 (es) "un procedimiento para la preparacion de derivados de pirrolidina".
BR9503536A (pt) Composto processo para sua preparação seu uso e composição farmacêutica
IL111184A (en) Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
DE3264415D1 (en) The crystalline anhydrous form of (3s-(3 alpha(z),4 beta))-3-(((2-amino-4-thiazolyl)(1-carboxy-1-methylethoxy)-imino)-acetyl)-amino)-4-methyl-2-oxo-1-azetidinesulfonic acid, method for its preparation, mixture and pharmaceutical composition containing it
KR900700098A (ko) 발기부전의 치료겸 진단용 플라복세이트 및 그 유도체
KR900001715A (ko) Bu-3608 유도체
KR910005871A (ko) 세팔로스포린계 주사용 제제
ATE21509T1 (de) Beta-lactam-essigsaeure-derivate, verfahren zu deren herstellung und deren verwendung als zwischenverbindungen fuer 1-azabicyclo(3.2.0)hept- 2-en-antibiotika.
KR870007164A (ko) 모노술팍탐
ES8506731A1 (es) Un procedimiento para preparar derivados de cefalosporina
KR930006003A (ko) 이미다졸릴메틸-피리딘류 화합물
FI913713A0 (fi) Nya bicykliska aminosubstituerade foereningar.
KR890002111A (ko) 벤즈이미다졸 유도체, 그의 제법 및 치료에의 이용
KR880007528A (ko) [3s(z)]-2[[[1-(2-아미노-4-티아졸릴)-2-[[2,2-디메틸-4-옥소-1-(술포옥시)-3-아제티디닐]아미노]-2-옥소에틸리덴]아미노]옥시]아세트산의 결정질 염류
KR890003755A (ko) 7- (2- 메틸- 4- 아미노피롤리디닐)나프티리딘 및 퀴놀린 화합물
KR920014811A (ko) 트리사이클릭 피리돈 유도체
KR850000454A (ko) 세팔로스포린 유도체의 제조방법
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물
SE8804696L (sv) Dioxazocin- derivat, deras framstaellning och beredningar innehaallande desamma
HK1007428A1 (en) (alfa-t-butyl aminomethyl-3,4-dichlorobenzyl) thioacetamide process for its preparation and its applications
DE3262231D1 (en) A novel vasodilator compound, process for the preparation thereof and pharmaceutical compositions thereform

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

J2X2 Appeal (before the supreme court)

Free format text: APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL